Literature DB >> 21254970

In vitro models for the study of non-alcoholic fatty liver disease.

N C Chavez-Tapia1, N Rosso, C Tiribelli.   

Abstract

Non-alcoholic fatty liver disease is regarded as the hepatic manifestation of metabolic syndrome and is an important and common cause of chronic liver disease with a potential to develop end-stage liver disease. While important advances in the pathophysiology have been achieved using genetically modified and diet-induced animal models, in-vitro models have been only recently proposed. These models include primary culture and immortalized cell lines. Here we critically review the characteristics of the in vitro models described, the advantages and limitations of the in vitro approach, and the results derived.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21254970     DOI: 10.2174/092986711794940842

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  17 in total

1.  Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E.

Authors:  Ning Ma; Yanqi Hou; Heidi Coia; Marcin D Dyba; Ying Fu; M Idalia Cruz; Carlos Benitez; Garrett T Graham; Justine N McCutcheon; Yun-Ling Zheng; Bing Sun; Bhaskar V Kallakury; Junfeng Ma; Hong-Bin Fang; Deborah L Berry; Vinona Muralidaran; Fung-Lung Chung
Journal:  Cancer Prev Res (Phila)       Date:  2018-08-21

Review 2.  Obesity III: Obesogen assays: Limitations, strengths, and new directions.

Authors:  Christopher D Kassotis; Frederick S Vom Saal; Patrick J Babin; Dominique Lagadic-Gossmann; Helene Le Mentec; Bruce Blumberg; Nicole Mohajer; Antoine Legrand; Vesna Munic Kos; Corinne Martin-Chouly; Normand Podechard; Sophie Langouët; Charbel Touma; Robert Barouki; Min Ji Kim; Karine Audouze; Mahua Choudhury; Nitya Shree; Amita Bansal; Sarah Howard; Jerrold J Heindel
Journal:  Biochem Pharmacol       Date:  2022-04-05       Impact factor: 6.100

Review 3.  Translational approaches: from fatty liver to non-alcoholic steatohepatitis.

Authors:  Natalia Rosso; Norberto C Chavez-Tapia; Claudio Tiribelli; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

4.  Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease.

Authors:  Norberto C Chavez-Tapia; Natalia Rosso; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2012-03-01       Impact factor: 3.067

5.  Hepatitis C Virus Increases Free Fatty Acids Absorption and Promotes its Replication Via Down-Regulating GADD45α Expression.

Authors:  Wei Chen; Xiao-Ming Li; An-Ling Li; Gui Yang; Han-Ning Hu
Journal:  Med Sci Monit       Date:  2016-07-06

6.  Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease.

Authors:  Tomasz Kostrzewski; Terri Cornforth; Sophie A Snow; Larissa Ouro-Gnao; Cliff Rowe; Emma M Large; David J Hughes
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

Review 7.  Bioengineered Multicellular Liver Microtissues for Modeling Advanced Hepatic Fibrosis Driven Through Non-Alcoholic Fatty Liver Disease.

Authors:  Hyun-Jong Cho; Han-Jun Kim; KangJu Lee; Soufian Lasli; Aly Ung; Tyler Hoffman; Rohollah Nasiri; Praveen Bandaru; Samad Ahadian; Mehmet R Dokmeci; Junmin Lee; Ali Khademhosseini
Journal:  Small       Date:  2021-03-09       Impact factor: 13.281

Review 8.  In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).

Authors:  Giridhar Kanuri; Ina Bergheim
Journal:  Int J Mol Sci       Date:  2013-06-05       Impact factor: 5.923

9.  Specific inhibition of the redox activity of ape1/ref-1 by e3330 blocks tnf-α-induced activation of IL-8 production in liver cancer cell lines.

Authors:  Laura Cesaratto; Erika Codarin; Carlo Vascotto; Antonio Leonardi; Mark R Kelley; Claudio Tiribelli; Gianluca Tell
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

10.  Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells.

Authors:  Eungyeong Jang; Min-Hee Shin; Ki-Suk Kim; Yoomi Kim; Yun-Cheol Na; Hong-Jung Woo; Youngchul Kim; Jang-Hoon Lee; Hyeung-Jin Jang
Journal:  BMC Complement Altern Med       Date:  2014-07-19       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.